| abstract |
FIELD: medicine. n SUBSTANCE: invention relates to medicine, namely to psychiatry, and can be used to predict the effectiveness of treatment of schizophrenia patients with the olanzapine atypical antipsychotic drug. For this purpose, immune status of patients with schizophrenia is analyzed before the start of therapy, the level of cortisol in the blood serum is determined and with the simultaneous content of T-helper/inducer (CD4 + ) more than 41 %, natural killers (CD16 + ) more than 11 %, serum levels of cortisol of more than 727 nmol/l the high effectiveness of atypical antipsychotic drug therapy is predicted. n EFFECT: invention provides an expansion of the arsenal of methods for predicting the effectiveness of therapy for patients with schizophrenia before prescribing active psychopharmacological treatment with antipsychotics. n 1 cl, 1 tbl, 2 ex |